Completion Rates of Recommended Vaccines Lower for Preemies
WEDNESDAY, Aug. 7, 2019 -- Preterm infants, including those born late preterm, have a lower rate of completion of recommended vaccines by age 19 months, according to a study published online Aug. 7 in Pediatrics.
Annika M. Hofstetter, M.D., Ph.D., M.P.H., from the University of Washington in Seattle, and colleagues conducted a retrospective cohort study involving 10,367 Washington state infants with birth hospitalizations during 2008 to 2013. Completion of the recommended seven-vaccine series by 19 months of age was compared for preterm infants and term/postterm infants (born at <37 weeks of gestation and born at 37 to 43 weeks of gestation, respectively).
Overall, 19.3 percent of the infants were born prematurely. The researchers found that compared with term/postterm infants, preterm infants had lower completion of the seven-vaccine series by 19 months (47.5 versus 54.0 percent; adjusted odds ratio, 0.77) and 36 months (63.6 versus 71.3 percent; adjusted odds ratio, 0.73). Compared with term/postterm infants, early preterm (23 to 33 weeks of gestation) and late preterm (34 to 36 weeks of gestation) infants had a lower rate of seven-vaccine series completion. Between-group differences were also seen for full influenza coverage by 19 months (early preterm, 47.7 percent; late-preterm, 41.5 percent; term/postterm, 44.7 percent).
"The reasons for this are unclear but could reflect parental and provider factors, such as perceptions of medical vulnerability, vaccine safety beliefs, understanding of current vaccine recommendations, and provider-family vaccine communication, as well as health care use patterns in these high-risk infants," the authors write.
© 2020 HealthDay. All rights reserved.
Posted: August 2019
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.